I have a feeling that the caliber of the news and the market’s reaction will be less than the most devoted shareholders hope. I do not for example expect that the last year involved any movement toward approval and that the clock on the approval process will basically start when TLD is released. NWBO wanted the journal yo convince regulators and not just the investing public, doctors and scientists.
The idea that this extra year+ since September 2020 not to mention the extra time tacked on by going from PFS to OS and before that by adding patients is going to bring us an unstoppable perfect storm of great news to drown the sinning shorts while we sit in the Ark is too much faith and not enough finance.
Still, I have my seat on the Ark either way, whether it floats or not.
Market Data 
Markets 
AI
